Open an account

Avid Bioservices

CDMO · NASDAQ

Price unavailable right now.

No price history for this range.

About CDMO

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials for the treatment and diagnosis of cancer. The company is headquartered in Tustin, California and currently employs 371 full-time employees. The firm provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the Company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of its services ranges from standalone process development projects to full development and manufacturing programs through commercialization. Commercial biologics produced by it are distributed to over 90 countries.

Employees
371
Headquarters
Tustin, California
Listed
Oct 27, 1993
Sector
Health Care
Industry
Biotechnology
Website
avidbio.com

CDMO key statistics

This section is temporarily unavailable. Refresh to try again.

CDMO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 128.0% on average.

  1. Q3 FY23: reported $0.01 per share against an estimate of -$0.0357
  2. Q4 FY23: reported $0.00 per share against an estimate of $0.00
  3. Q1 FY24: reported -$0.03 per share against an estimate of -$0.0281
  4. Q2 FY24: reported -$0.15 per share against an estimate of -$0.0638
  5. Q3 FY24: reported -$0.09 per share against an estimate of -$0.0536
  6. Q4 FY24: reported -$1.94 per share against an estimate of -$0.0383
  7. Q1 FY25: reported -$0.09 per share against an estimate of -$0.0561
  8. Q2 FY25: reported -$0.27 per share against an estimate of -$0.1199

CDMO news

  • Press releasePRNewswire

    SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates CDMO, AE, SUM, BCOV on Behalf of Shareholders

  • Press releaseBusiness Wire

    AVID BIOSERVICES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avid Bioservices, Inc. - CDMO

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CDMO, ATSG, STAF on Behalf of Shareholders

  • Press releaseBusiness Wire

    CDMO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avid Bioservices, Inc. Is Fair to Shareholders

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALTR, MPB, CDMO, AVAV on Behalf of Shareholders

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZUO, CDMO, BRKH on Behalf of Shareholders

  • Press releaseBusiness Wire

    CDMO Investors Have the Opportunity to Join Investigation of Avid Bioservices, Inc. with the Schall Law Firm

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALVR, CDMO, EMKR on Behalf of Shareholders

Similar companies

Companies in the same industry as Avid Bioservices

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.